1360628-91-6
Chemical Structure
M3541
- CAS No.: 1360628-91-6
- Formula:C23H17FN6O2
- Molecular Weight:428.42
InChIKey: OOCGUVCGJIUQKC-UHFFFAOYSA-N
SMILES: N#CC1=CC=C(N(C2=C3C=NC4=CC(OC)=C(C5=CN(C)N=C5)C=C24)C(N3C)=O)C(F)=C1
Biological Activity: M3541 is an orally effective DNA-dependent protein kinase (DNA-PK) inhibitor. M3541 inhibits ionizing radiation-induced ATM autophosphorylation and phosphorylation of downstream substrates (KAP1, CHK2, p53), blocks DSB end resection and homologous recombination repair, and simultaneously induces non-homologous end joining, G2-M phase arrest, polyploidization, and cell death. M3541 can be used for research on solid tumors, acute myeloid leukemia, non-small cell lung cancer, triple-negative breast cancer, etc.[1][2][3][4][5][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
M3541 | 99.28% | M3541 is an orally effective DNA-dependent protein kinase (DNA-PK) inhibitor. M3541 inhibits ionizing radiation-induced ATM autophosphorylation and phosphorylation of downstream substrates (KAP1, CHK2, p53), blocks DSB end resection and homologous recombination repair, and simultaneously induces non-homologous end joining, G2-M phase arrest, polyploidization, and cell death. M3541 can be used for research on solid tumors, acute myeloid leukemia, non-small cell lung cancer, triple-negative breast cancer, etc.. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zimmermann A, et al. A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies. Molecular cancer therapeutics. 2022 Jun 01;21(6):859-870. [Content Brief]
- [2]. Carr MI, et al. DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia. Frontiers in oncology. 2020;10:127.
- [3]. Cai MY, et al. Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection. Cell reports. 2020 Feb 18;30(7):2402-2415.e5.
- [4]. Zhang H, et al. Mapping combinatorial drug effects to DNA damage response kinase inhibitors. Nature communications. 2023 Dec 14;14(1):8310.
- [5]. Turchick A, et al. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors. Molecular cancer therapeutics. 2023 Jul 05;22(7):859-872.
- [7]. Zimmermann A, et al. Abstract 338: A new investigational ATM Inhibitor, M3541, synergistically potentiates fractionated radiotherapy and chemotherapy in cancer cells and animal models. Cancer Res. 2018;78(13_Suppl):338.
- [8]. Fuchss T, et al. Imidazolylchinoline [Patent]. DE 102010035744 A1. Germany; 2012‑03‑01.
- [9]. Chiu LY, et al. Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death. Aging. 2023 Jan 17;15(2):492-512.
- [10]. Fuchss T, et al. Abstract 329: Highly potent and selective ATM kinase inhibitor M3541: A clinical candidate drug with strong antitumor activity in combination with radiotherapy. Cancer Res. 2018;78(13_Suppl):329.
